These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 22409290)

  • 21. Comparative analysis of budesonide/formoterol and fluticasone/salmeterol combinations in COPD patients: findings from a real-world analysis in an Italian setting.
    Perrone V; Sangiorgi D; Buda S; Degli Esposti L
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2749-2755. PubMed ID: 27853362
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost Effectiveness of the Long-Acting β2-Adrenergic Agonist (LABA)/Long-Acting Muscarinic Antagonist Dual Bronchodilator Indacaterol/Glycopyrronium Versus the LABA/Inhaled Corticosteroid Combination Salmeterol/Fluticasone in Patients with Chronic Obstructive Pulmonary Disease: Analyses Conducted for Canada, France, Italy, and Portugal.
    Reza Maleki-Yazdi M; Molimard M; Keininger DL; Gruenberger JB; Carrasco J; Pitotti C; Sauvage E; Chehab S; Price D
    Appl Health Econ Health Policy; 2016 Oct; 14(5):579-94. PubMed ID: 27516088
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhanced persistence with tiotropium compared with other respiratory drugs in COPD.
    Breekveldt-Postma NS; Koerselman J; Erkens JA; Lammers JW; Herings RM
    Respir Med; 2007 Jul; 101(7):1398-405. PubMed ID: 17368011
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness and budget impact of the fixed-dose dual bronchodilator combination tiotropium-olodaterol for patients with COPD in the Netherlands.
    van Boven JF; Kocks JW; Postma MJ
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2191-2201. PubMed ID: 27703341
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.
    Keam SJ; Keating GM
    Treat Respir Med; 2004; 3(4):247-68. PubMed ID: 15350163
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-acting bronchodilator therapy for the treatment of chronic obstructive pulmonary disease.
    Chen AM; Bollmeier SG; Finnegan PM
    Ann Pharmacother; 2008 Dec; 42(12):1832-42. PubMed ID: 18957624
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in adults and children aged 12 years and over.
    Shepherd J; Rogers G; Anderson R; Main C; Thompson-Coon J; Hartwell D; Liu Z; Loveman E; Green C; Pitt M; Stein K; Harris P; Frampton GK; Smith M; Takeda A; Price A; Welch K; Somerville M
    Health Technol Assess; 2008 May; 12(19):iii-iv, 1-360. PubMed ID: 18485271
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of long-acting bronchodilators for chronic obstructive pulmonary disease.
    Oba Y
    Mayo Clin Proc; 2007 May; 82(5):575-82. PubMed ID: 17493425
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries.
    Nielsen R; Kankaanranta H; Bjermer L; Lange P; Arnetorp S; Hedegaard M; Stenling A; Mittmann N
    Respir Med; 2013 Nov; 107(11):1709-21. PubMed ID: 23856511
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Estimating the cost-effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease in the presence of missing data.
    Briggs AH; Lozano-Ortega G; Spencer S; Bale G; Spencer MD; Burge PS
    Value Health; 2006; 9(4):227-35. PubMed ID: 16903992
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of salmeterol, fluticasone, and combination therapy for COPD.
    Oba Y
    Am J Manag Care; 2009 Apr; 15(4):226-32. PubMed ID: 19355795
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical and economic outcomes associated with the use of fluticasone propionate 250 mcg and salmeterol 50 mcg combination versus tiotropium bromide 18 mcg as initial maintenance treatment for chronic obstructive pulmonary disease in managed care.
    Bell CF; Coutinho AD; Farrelly E; Lokhandwala T; Landsman-Blumberg P
    J Med Econ; 2018 Jun; 21(6):629-638. PubMed ID: 29577787
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The cost-saving switch from inhaled corticosteroid-containing treatments to dual bronchodilation: a two-country projection of epidemiological and economic burden in chronic obstructive pulmonary disease.
    Souliotis K; Silva Miguel L; Hillas G; Borges M; Papageorgiou G; Viana D; Malhadeiro J; Soulard S
    Ther Adv Respir Dis; 2020; 14():1753466620926802. PubMed ID: 32519591
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Which long-acting bronchodilator is most cost-effective for the treatment of COPD?
    Hoogendoorn M; Kappelhoff BS; Overbeek JA; Wouters EF; Rutten-van Mölken MP
    Neth J Med; 2012 Oct; 70(8):357-64. PubMed ID: 23065983
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Economic evaluation of treating chronic obstructive pulmonary disease with inhaled corticosteroids and long-acting beta2-agonists in a health maintenance organization.
    Gagnon YM; Levy AR; Spencer MD; Hurley JS; Frost FJ; Mapel DW; Briggs AH
    Respir Med; 2005 Dec; 99(12):1534-45. PubMed ID: 16291076
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Benefits and risks of adjunctive inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis.
    Sobieraj DM; White CM; Coleman CI
    Clin Ther; 2008 Aug; 30(8):1416-25. PubMed ID: 18803985
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost effectiveness of tiotropium for chronic obstructive pulmonary disease: a systematic review of the evidence.
    Mauskopf JA; Baker CL; Monz BU; Juniper MD
    J Med Econ; 2010; 13(3):403-17. PubMed ID: 20608887
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease.
    Welsh EJ; Cates CJ; Poole P
    Cochrane Database Syst Rev; 2013 May; (5):CD007891. PubMed ID: 23728670
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcomes and costs of treating chronic obstructive pulmonary disease with inhaled fixed combinations: the Italian perspective of the PATHOS study.
    Roggeri A; Micheletto C; Roggeri DP
    Int J Chron Obstruct Pulmon Dis; 2014; 9():569-76. PubMed ID: 24940053
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The impact of inhaled corticosteroid and long-acting beta-agonist combination therapy on outcomes in COPD.
    Hanania NA
    Pulm Pharmacol Ther; 2008; 21(3):540-50. PubMed ID: 18280761
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.